trial

Characterizing Response to Antipsychotics in Schizophrenia

NCTId NCT06159322
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 40 (estimated)
Sponsored by The Royal Ottawa Mental Health Centre
Primary completion 2024-01-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
40 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2023-01-01
Primary completion
2024-01-30
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
OlanzapineClozapine

Sponsors

The Royal Ottawa Mental Health CentreLead Sponsor
The Royal's Institute of Mental Health ResearchCollaborator

Investigators

2
Lauri Tuominen, MD, PhDPrincipal Investigator
Clifford Cassidy, PhDPrincipal Investigator

Sites

1 total
Ottawa, Canada

Facts & assertions

4 sourced
Enrollment
40
Phase
NA
Primary Completion Date
2024-01-30
Status
UNKNOWN
relationships
The graph out of here
drug
Olanzapine
drug
Clozapine
drug
lead_sponsor
The Royal Ottawa Mental Health Centre
company
collaborator
The Royal's Institute of Mental Health Research
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Lauri Tuominen, MD, PhD
person
Clifford Cassidy, PhD
person